- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01544816
Evaluating the Effects of Snack Products on Energy
6. mai 2013 oppdatert av: Mondelēz International, Inc.
To determine the effect of snack products varying in composition, on energy in healthy adult subjects.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
49
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30341
- Mercer University Center for Clinical Research
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
20 år til 45 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- The subject must provide informed consent.
- The subject is male or female, and between the ages of 20 and 45, inclusive.
- The subject is a routine, moderate daily user of caffeine (approximately 1-4 cups of coffee or equivalent).
- The subject is fluent in English.
- The subject has a minimum of a high school diploma.
- Females of Child-bearing Potential (FOCP) must have a negative urine or serum beta HCG pregnancy test at screening. FOCP must abstain from sexual activity that could result in a pregnancy, or use acceptable contraceptives throughout the period of study treatment exposure. Acceptable contraceptives include IUDs, hormonal contraceptives (oral, implanted or injectable) and double barrier methods (such as condom or diaphragm with spermicidal gel). If hormonal contraceptives are used, the period of use must be sufficiently long to achieve pharmacological effectiveness prior to study treatment exposure (refer to individual product information for details on onset of effectiveness). FOCP who are not currently sexually active, must agree to use acceptable contraception, as defined above, if they decide to become sexually active during the period of study treatment exposure .
- The subject is in good physical and mental health based on a general medical history.
- The subject has adequate visual and auditory acuity and cognitive ability to complete the assessments and is capable of understanding and following instructions for the performance tests within the normal, age-adjusted range (within one SD) at screening.
- Must be able and willing to obtain a minimum of 7 hours of sleep the night prior to each study visit.
- The subject is willing and able to comply with all requirements defined within this protocol.
- The subject reports having a snack at least two afternoons per week.
- The subject reports experiencing an "afternoon slump".
Exclusion Criteria
- The subject has a current Axis I or Axis II comorbid psychiatric diagnosis or other symptomatic manifestations that, in the opinion of the examining physician (Investigator), will contraindicate treatment with caffeine.
- Attention Deficit Disorder or Attention Deficit Hyperactivity Disorder
- BMI ≤ 19 or ≥ 30 kg/m2.
- The subject has documented allergies, adverse reactions, or intolerance to caffeine.
- The subject has any significant medical illness or condition for which caffeine is contraindicated.
- The subject has a history of drug dependence or substance use disorder based upon DSM-IV-TR criteria (excluding nicotine).
- The subject has a positive urine drug or alcohol drug test result (to include nicotine).
- The subject has participated in an investigational study or received an investigational drug within the past 28 days.
- The subject has used nicotine products within 30 days of screening or during the duration of the study.
- The subject is taking medications, that have CNS effects or affect performance, (such as sedating antihistamines and decongestant sympathomimetics, either oral or topical), and may interfere with efficacy or safety assessments.
- The subject has a concurrent chronic or acute illness (such as allergic rhinitis or severe cold), disability, or other condition that might confound the results of rating tests administered in the study or that might increase risk to the subject. Similarly, the subject will be excluded if he or she has any additional conditions that, in the Investigator's opinion, would preclude the subject from completing the study or would not be in the best interest of the subject. This would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol.
- The female subject is pregnant or lactating or planning on becoming pregnant during the study
- Hypertension or other chronic medical conditions
- Individuals who do not maintain a routine nighttime sleep schedule (e.g. no shift work).
- Individuals judged by the Investigator to be unsuitable for enrollment in this study for any reason.
- The subject has been diagnosed with phenylketonuria.
- Inability to perform performance tests within the Normal range (i.e., performance no lower than 1SD below the mean) at screening.
- The subject has a pre-existing medical condition.
- Subject has been diagnosed with a sleeping disorder.
- Subject has a fasting glucose of >110 mg/dl.
- Subject has an allergy to wheat, soy, nuts or other food.
- Subject has Kosher or Halal dietary restrictions.
- Subject reports never eating biscuits, cookies or crackers.
- Epworth Sleepiness Scale ≥ at screening (i.e., evidence of excessive daytime sleepiness).
- Dislike of chocolate flavorings
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Placebo komparator: Control Food Product
Control food product
|
control food product
Experimental food product containing ingredient 1
Experimental food product containing ingredient 2
|
Eksperimentell: Experimental Food Product 1
Experimental food product 1
|
control food product
Experimental food product containing ingredient 1
Experimental food product containing ingredient 2
|
Eksperimentell: Experimental Food Product 2
Experimental food product 2
|
control food product
Experimental food product containing ingredient 1
Experimental food product containing ingredient 2
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Energy questionnaire OR Rating of perceived energy OR Subjective feeling of energy (visual analog scale)
Tidsramme: 90 minutes post snack
|
90 minutes post snack
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Chad VanDenBerg, Pharm.D., Mercer University
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. februar 2012
Primær fullføring (Faktiske)
1. august 2012
Studiet fullført (Faktiske)
1. august 2012
Datoer for studieregistrering
Først innsendt
24. februar 2012
Først innsendt som oppfylte QC-kriteriene
29. februar 2012
Først lagt ut (Anslag)
6. mars 2012
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
8. mai 2013
Siste oppdatering sendt inn som oppfylte QC-kriteriene
6. mai 2013
Sist bekreftet
1. mai 2013
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- KFG-123X-01
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Energi
-
University of Colorado, DenverFullførtSkade på havnestedet forårsaket av Stray Energy TransferForente stater
-
University of ReadingBiotechnology and Biological Sciences Research Council; The Norwegian Institute... og andre samarbeidspartnereHar ikke rekruttert ennåProtein-Energy UnderernæringStorbritannia
-
Hospital General Universitario Gregorio MarañonInstituto de Salud Carlos III; European Regional Development Fund; Maternal...UkjentProtein-Energy UnderernæringSpania
-
Assistance Publique - Hôpitaux de ParisFullførtProtein-Energy UnderernæringFrankrike
-
An Hsin QingShui ClinicFullført
-
Semarang Health PolytechnicUkjentAnemi | Svangerskap | Protein-Energy UnderernæringIndonesia
-
Seoul St. Mary's HospitalFullførtProtein-Energy UnderernæringKorea, Republikken
-
University of FloridaAktiv, ikke rekrutterendeNyresvikt | Protein-Energy UnderernæringForente stater
-
VU University of AmsterdamAmsterdam UMC, location VUmc; University of HelsinkiFullførtFysisk hemmet | Protein-Energy UnderernæringFinland, Nederland
-
Action Contre la FaimJohns Hopkins UniversityUkjent
Kliniske studier på Snack Product
-
Radicle ScienceAktiv, ikke rekrutterendeKognitiv funksjonForente stater
-
Mondelēz International, Inc.Reading Scientific Services Ltd.Fullført
-
Radicle ScienceRekrutteringSmerte | Nevropatisk smerte | Nociseptiv smerteForente stater
-
USDA, Western Human Nutrition Research CenterAlmond Board of CaliforniaAvsluttet
-
Vanderbilt UniversityAgency for Healthcare Research and Quality (AHRQ)Fullført
-
Ryerson UniversityThe Hershey CompanyFullførtMatinntak | MetthetCanada
-
University of Colorado, DenverAmerican Pecan CouncilFullførtOvervekt og fedmeForente stater
-
Radicle ScienceAktiv, ikke rekrutterendeKognitiv funksjonForente stater
-
King's College LondonHar ikke rekruttert ennåDepresjon | AngstStorbritannia
-
King's College LondonRekrutteringImmun responsStorbritannia